Drug Induced Liver Injury
Note: this meeting was held March 14-15, 2012
Why DILI Idiosyncrasy? The Immune System and Beyond ...
Why Do Only A Few People Show Serious Liver Dysfunction
From Drugs That Nearly Everybody Else Can Tolerate or Adapt To?
Co-sponsored by FDA/CDER, C-Path, and PhRMA
Endorsed by NIH DILIN and AASLD
John R. Senior, MD and Lana Pauls, MPH
Mark Avigan, MD, CM; Robert Fontana, MD; Christine Hunt, MD; Michael Merz, MD; Arie Regev, MD; Leonard Seeff, MD and Paul Watkins, MD
DILI is still a major problem for drug development, and a clinical concern after marketing. We need new biomarkers, new understanding, and a path forward to solve the problems. This academic-industry-government international conference will discuss new findings and thinking about drug-induced liver injury (DILI), including presentations by experts in clinical hepatology, toxicology, and other fields, and discussion with all registrants. Come and participate in this conference.
Open Discussion of FDA 2009 Guidance Revision
Presentations (Note: Click on the Presentation Title to view slides)